Horizon Therapeutics Public (NASDAQ:HZNP) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.
Insider & Institutional Ownership
88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Horizon Therapeutics Public and BridgeBio Pharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Horizon Therapeutics Public | 43.55% | 25.66% | 14.19% |
BridgeBio Pharma | N/A | -109.88% | -48.54% |
Earnings & Valuation
This table compares Horizon Therapeutics Public and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Horizon Therapeutics Public | $1.30 billion | 16.12 | $573.02 million | $1.94 | 48.20 |
BridgeBio Pharma | $40.56 million | 201.80 | $-260,590,000.00 | ($2.48) | -22.16 |
Horizon Therapeutics Public has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Horizon Therapeutics Public and BridgeBio Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Horizon Therapeutics Public | 0 | 0 | 11 | 0 | 3.00 |
BridgeBio Pharma | 0 | 1 | 9 | 0 | 2.90 |
Horizon Therapeutics Public presently has a consensus target price of $111.3636, indicating a potential upside of 19.09%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Horizon Therapeutics Public.
Volatility & Risk
Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Summary
Horizon Therapeutics Public beats BridgeBio Pharma on 10 of the 14 factors compared between the two stocks.